Latest in Cardiology from ACC.org

• Genotype-First Approach to Cardiomyopathy Outcomes
  What is the risk of mortality and composite cardiomyopathy-related outcomes associated with predicted deleterious variants in cardiomyopathy-associated genes?
• SGLT2 Inhibitors and Major Adverse CV Outcomes
  What is the effect of sodium glucose co-transporter 2 inhibitors (SGLT2i) on the risk of major adverse cardiovascular events (MACE) and its individual components, overall and within clinically relevant subgroups of patients, irrespective of atherosclerotic cardiovascular disease (ASCVD), diabetes, and kidney function?
• FDA Update: Heartmate II and Heartmate 3 LVAS Recalled Due to Obstruction
  The U.S. Food and Drug Administration (FDA) announced on April 15 that Abbott/Thoratec Corp. is recalling the Heartmate II and Heartmate 3 Left Ventricular Assist System (LVAS) due to long-term buildup of biological material causing an obstruction in the device, making it more difficult for the heart to pump blood.
• Eagle’s Eye View: Infective Endocarditis After Invasive Dental Procedures, Serious Bleeding in Patients with Atrial Fibrillation (AFib) Using Diltiazem with Apixaban or Rivaroxaban and Low-Dose Colchicine for Secondary Prevention in Atherosclerosis
  In this week’s View, Dr. Eagle looks at a systematic review and meta-analysis of antibiotic prophylaxis and infective endocarditis incidence following invasive dental procedures. He then examines the issue of serious bleeding in patients with atrial fibrillation using diltiazem with apixaban or rivaroxaban.
• American and European HF Guideline Comparison: Key Points
  The following are key points to remember from a review comparing contemporary clinical practice recommendations for the management of heart failure (HF) in the American and European guidelines.